Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Adverum Biotechnologies, Inc. ADVM NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
41/100
3/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$15.00
+244%

Adverum Biotechnologies, Inc. (ADVM) is a Biotechnology company in the Healthcare sector, currently trading at $4.36. It has a SharesGrow Score of 41/100, indicating a mixed investment profile with 3 out of 7 criteria passed.

Analyst consensus target is ADVM = $15 (+244% upside).

Financials: revenue is $1M, -86.1%/yr average growth. Net income is $131M (loss), growing at +2.1%/yr. Net profit margin is -13092.7% (negative). Gross margin is -265.3% (-303.4 pp trend).

Balance sheet: total debt is $92M against $71M equity (Debt-to-Equity (D/E) ratio 1.3, moderate). Current ratio is 5.73 (strong liquidity). Debt-to-assets is 51%. Total assets: $180M.

Analyst outlook: 10 / 16 analysts rate ADVM as buy (63%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 30/100 (Fail), Past 0/100 (Fail), Health 75/100 (Pass), Moat 0/100 (Fail), Future 73/100 (Pass), Income 10/100 (Fail).

$15.00
▲ 244.04% Upside
Average Price Target
Based on 16 Wall Street analysts offering 12-month price targets for Adverum Biotechnologies, Inc., the average price target is $15.00, with a high forecast of $28.00, and a low forecast of $2.00.
Highest Price Target
$28.00
Average Price Target
$15.00
Lowest Price Target
$2.00

ADVM SharesGrow Score Overview

58/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 30/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 75/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 0/100
Gross margin is + market cap
FUTURE 73/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ADVM

✓
VALUE Pass
100/100
ADVM trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $15, implying +244% from the current price $4. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
30/100
ADVM: -86.1%/yr revenue is, +2.1%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
75/100
Balance sheet ADVM: Debt-to-Equity (D/E) ratio 1.3 (moderate), Current ratio is 5.73 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
—
MOAT N/A
N/A
No analyst coverage available for this stock.
✓
FUTURE Pass
73/100
Analyst outlook: 10 / 16 analysts rate ADVM as buy (63%). Analyst consensus target is $15 (+244% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
ADVM: Net profit margin is -13092.7%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range1.78-6.07
Volume675.98K
Avg Volume (30D)724.34K
Market Cap$96.26M
Beta (1Y)0.87
Share Statistics
EPS (TTM)-6.62
Shares Outstanding$19.78M
IPO Date2014-07-31
Employees155
CEOLaurent Fischer
Financial Highlights & Ratios
Revenue (TTM)$1M
Gross Profit$-2.65M
EBITDA$-127.27M
Net Income$-130.93M
Operating Income$-139.16M
Total Cash$125.69M
Total Debt$91.71M
Net Debt$31.05M
Total Assets$179.84M
Price / Earnings (P/E)-0.7
Price / Sales (P/S)96.26
Analyst Forecast
1Y Price Target$15.00
Target High$28.00
Target Low$2.00
Upside+244.0%
Rating ConsensusBuy
Analysts Covering16
Buy 63% Hold 38% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Market
CurrencyUSD
ISINUS00773U2078

Price Chart

Track all markets on TradingView
ADVM
Adverum Biotechnologies, Inc. ↗  ·  NASDAQ Global Market
Healthcare • Biotechnology
1.78 52WK RANGE 6.07

People Also View

RYTM
RYTM
Rhythm Pharmaceuticals, Inc.
$87.28
+0.54%
 KOD
KOD
Kodiak Sciences Inc.
$45.07
+7.44%
 STOK
STOK
Stoke Therapeutics, Inc.
$35.86
+2.31%
 QURE
QURE
uniQure N.V.
$17.09
-4.63%
 MGTX
MGTX
MeiraGTx Holdings plc
$11.29
+17.24%
 SLDB
SLDB
Solid Biosciences Inc.
$8.23
-1.91%
 ABSI
ABSI
Absci Corporation
$3.15
+3.28%
 RCKT
RCKT
Rocket Pharmaceuticals, Inc.
$3.64
+0.14%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message